News Study shows AZ's Farxiga diabetes drug cuts heart risks AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial.
News Pfizer drug reduces mortality in patients with fatal heart d... Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.
Views & Analysis SGLT2 inhibitors: an emerging option for cardiologists? With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.
News NHS England okays funding for cholesterol-lowering drug Lojuxta will be available to patients this year
News Amgen's Repatha gets EU cardio risk reduction label But Sanofi/Regeneron could have advantage thanks to price cut and better data
News EU approves AZ's potential blockbuster hyperkalaemia drug After manufacturing issues, AstraZeneca hopes for FDA nod soon.
News UK digital health funding should be ringfenced, says report IT industry group techUK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
